Stoke Therapeutics Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Ian Smith
Chief executive officer
US$248.3k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 2.7yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
CEO
Ian Smith (58 yo)
Mr. Ian F. Smith, CPA, ACA, is Director of Areteia Therapeutics, Inc. from March 26, 2025. He is an Interim CEO of Stoke Therapeutics, Inc. from March 19, 2025. He is an Independent Director at Odyssey The...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim Executive Chairman | 6.7yrs | US$150.65k | 0.058% € 265.4k | |
| Interim CEO & Director | less than a year | US$248.25k | no data | |
| Co-Founder & Independent Director | no data | US$130.95k | 0.74% € 3.4m | |
| Chief Financial Officer | 1yr | US$4.69m | no data | |
| Advisor & Director | less than a year | US$5.61m | 0.26% € 1.2m | |
| Chief Medical Officer | 7.6yrs | US$2.47m | 0.062% € 284.3k | |
| Co-Founder | no data | no data | no data | |
| Director of Communications & Investor Relations | less than a year | no data | no data | |
| Corporate Secretary & General Counsel | 4.3yrs | no data | 0.058% € 264.0k | |
| Chief Communications Officer | 4.3yrs | no data | no data | |
| Chief Human Resources Officer | 5.6yrs | no data | no data | |
| Senior VP of Quality & Chief Regulatory Affairs Officer | 6.4yrs | no data | no data |
Experienced Management: 0GT's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim Executive Chairman | 6.7yrs | US$150.65k | 0.058% € 265.4k | |
| Interim CEO & Director | 1.7yrs | US$248.25k | no data | |
| Co-Founder & Independent Director | 10.9yrs | US$130.95k | 0.74% € 3.4m | |
| Advisor & Director | 7.6yrs | US$5.61m | 0.26% € 1.2m | |
| Independent Director | 9.8yrs | US$152.31k | 3.43% € 15.7m | |
| Independent Director | 9.7yrs | US$135.95k | 0.035% € 160.5k | |
| Independent Director | 4.8yrs | US$136.14k | 0% € 0 | |
| Independent Director | 4.9yrs | US$137.39k | 0% € 0 | |
| Independent Director | 5.9yrs | US$140.95k | 0% € 0 |
Experienced Board: 0GT's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 13:18 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stoke Therapeutics, Inc. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Thomas Shrader | BTIG |
| Michelle Gilson | Canaccord Genuity |